NCT02144012TERMINATEDanonymous

A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel as First-Line Treatment of Patients With Her2-Positive Progressive Or Recurrent Locally Advanced Or Metastatic Breast Cancer.

Sponsor

Source record

Hoffmann-La Roche

Phase

Source record

Phase III

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

HER2-positive Breast Cancer

Indication / condition

AI-normalized

Metastatic Breast Cancer

Intervention

Source record

Trastuzumab, Trastuzumab Emtansine, Docetaxel

Source & freshness

Source record

NCT ID

NCT02144012

Original source

ClinicalTrials.gov

Source last updated

Mar 07, 2017

Ingested at

Jun 05, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT02144012

Title

A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel as First-Line Treatment of Patients With Her2-Positive Progressive Or Recurrent Locally Advanced Or Metastatic Breast Cancer.

Sponsor

Hoffmann-La Roche

Status

TERMINATED

Phase

Phase III

Condition raw

Metastatic Breast Cancer

Condition normalized

Metastatic Breast Cancer

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Trastuzumab, Trastuzumab Emtansine, Docetaxel

Target normalized

HER2-positive Breast Cancer

Interventions

Trastuzumab, Trastuzumab Emtansine, Docetaxel

Public preview

Source record

This terminated clinical trial aimed to evaluate the efficacy and safety of trastuzumab emtansine compared to trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer. The study enrolled only 49 participants out of the planned 561, leading to its termination.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel as First-Line Treatment of Patients With Her2-Positive Progressive Or Recurrent Locally Advanced Or Metastatic Breast Cancer.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02144012

Status

TERMINATED

Phase

Phase III

Sponsor

Hoffmann-La Roche

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMar 07, 2017

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02144012

Indication

Metastatic Breast Cancer

Modality

monoclonal antibody

Target

HER2-positive Breast Cancer

Intervention

Trastuzumab, Trastuzumab Emtansine, Docetaxel

Source record